US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

12.57

-0.2100-1.64%

Post-market: 12.53-0.0400-0.32%19:46 EDT

Volume:282.36K

Turnover:3.57M

Market Cap:694.55M

PE:10.65

High:12.80

Open:12.77

Low:12.56

Close:12.78

52wk High:13.59

52wk Low:11.87

Shares:55.25M

Float Shares:55.25M

Volume Ratio:1.77

T/O Rate:0.51%

Dividend:1.42

Dividend Rate:11.26%

EPS(TTM):1.18

ROE:--

ROA:--

PB:0.87

PE(LYR):- -

Loading ...

Overview Company News Filings

Brookfield Real Assets Income Fund Announces Q1 2026 Monthly Distributions

Press Release: Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

CPF vs Dividend Stocks: Which Builds a Stronger Retirement Portfolio?

The Smart Investor

Press Release: Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Brookfield Real Assets Income Fund Inc. Announces Portfolio Manager Update Webcast

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

RA Capital discloses increased PepGen stake at 29%

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":12.57,"timestamp":1774641600000,"preClose":12.78,"halted":0,"volume":282361,"hourTrading":{"tag":"盘后","latestPrice":12.53,"preClose":12.57,"latestTime":"19:46 EDT","volume":352,"amount":4428.3,"timestamp":1774655160523,"change":-0.04,"changeRate":-0.003182,"amplitude":0.003182},"delay":0,"changeRate":-0.016431924882629036,"floatShares":55245934,"shares":55254696,"eps":1.18,"marketStatus":"Market Closed","change":-0.21,"latestTime":"03-27 16:00:00 EDT","open":12.77,"high":12.795,"low":12.56,"amount":3567019.4998935,"amplitude":0.018388,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.18,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":12.78,"dividendRate":0.112609,"preHourTrading":{"tag":"盘前","latestPrice":12.78,"preClose":12.78,"latestTime":"09:27 EDT","volume":2,"amount":25.55,"timestamp":1774618060039,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":12.53,"preClose":12.57,"latestTime":"19:46 EDT","volume":352,"amount":4428.3,"timestamp":1774655160523,"change":-0.04,"changeRate":-0.003182,"amplitude":0.003182},"volumeRatio":1.767883},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.767883,"shares":55254696,"dividePrice":1.4155,"high":12.795,"amplitude":0.018388,"preClose":12.78,"low":12.56,"week52Low":11.87,"pbRate":"0.87","week52High":13.59,"institutionHeld":0,"latestPrice":12.57,"eps":1.18,"divideRate":0.112609,"volume":282361,"delay":0,"ttmEps":1.18,"open":12.77,"prevYearClose":12.96,"prevWeekClose":12.57,"prevMonthClose":13.46,"prevQuarterClose":12.96,"fiveDayClose":12.57,"twentyDayClose":13.46,"sixtyDayClose":12.98},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-03-12","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-12","defaultRemindTime":1773322200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-26","payableDate":"2026-03-12","currency":"USD","dateTimestamp":1773288000000,"payDate":"2026-03-26"},{"date":"2026-02-05","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-05","defaultRemindTime":1770301800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-19","payableDate":"2026-02-05","currency":"USD","dateTimestamp":1770267600000,"payDate":"2026-02-19"},{"date":"2026-01-08","symbol":"RA","amount":0.118,"announcedDate":"2025-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-08","defaultRemindTime":1767882600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-22","payableDate":"2026-01-08","currency":"USD","dateTimestamp":1767848400000,"payDate":"2026-01-22"},{"date":"2025-12-11","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-11","defaultRemindTime":1765463400000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-11","currency":"USD","dateTimestamp":1765429200000,"payDate":"2025-12-26"},{"date":"2025-11-13","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-13","defaultRemindTime":1763044200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-28","payableDate":"2025-11-13","currency":"USD","dateTimestamp":1763010000000,"payDate":"2025-11-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2594213791","title":"Brookfield Real Assets Income Fund Announces Q1 2026 Monthly Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2594213791","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594213791?lang=en_us&edition=fundamental","pubTime":"2025-12-27 05:35","pubTimestamp":1766784956,"startTime":"0","endTime":"0","summary":"Brookfield Real Assets Income Fund Inc. has announced its monthly distribution schedule for the first quarter of 2026. The fund will pay distributions of $0.1180 per share on January 22, February 19, and March 26, 2026, to shareholders of record on January 8, February 5, and March 12, 2026, respectively.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brookfield Real Assets Income Fund Inc. published the original content used to generate this news brief via GlobeNewswire  on December 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251226:nNDL1kvMwX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210150020.SGD","RA","BK4588","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014013.SGD","SG9999014005.SGD","LU0314104364.USD","SG9999014039.USD","LU2095319765.USD","LU2210149790.SGD","BK4585","IE00BKPKM429.USD","NDAQ","BK4112"],"gpt_icon":0},{"id":"2593448733","title":"Press Release: Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448733","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593448733?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:01","pubTimestamp":1766523660,"startTime":"0","endTime":"0","summary":"BOSTON, Mass., Dec. 23, 2025  -- Vor Biopharma Inc. , a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company's recently announced $150M PIPE financing, which included participation from both investors.\"Andrew and Wouter bring highly complementary experience in life sciences investment, financing strategy, and board-level oversight. We are delighted to welcome them to our Board at an important moment for the Company,\" said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio. \"Their perspectives will be invaluable as we advance our global Phase 3 programs and position the Company to drive long-term shareholder value.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"gpt_icon":0},{"id":"2588988246","title":"Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588988246","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588988246?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:15","pubTimestamp":1764854100,"startTime":"0","endTime":"0","summary":"APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/04/3199763/0/en/Heron-Therapeutics-Announces-Inclusion-of-APONVIE-aprepitant-Injectable-Emulsion-in-the-Newly-Released-Fifth-Consensus-Guidelines-for-the-Management-of-Postoperative-Nausea-and-Vom.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HRTX","RA"],"gpt_icon":0},{"id":"2583652514","title":"Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583652514","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583652514?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067660,"startTime":"0","endTime":"0","summary":"Multiple Late-Stage Data Readouts Reinforce Telitacicept’s Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187807/0/en/Vor-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","SD","SLE","BK4213","BK4077"],"gpt_icon":0},{"id":"2583683055","title":"CPF vs Dividend Stocks: Which Builds a Stronger Retirement Portfolio?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583683055","media":"The Smart Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583683055?lang=en_us&edition=fundamental","pubTime":"2025-11-13 17:30","pubTimestamp":1763026200,"startTime":"0","endTime":"0","summary":"CPF offers guaranteed, risk-free returns, while dividend stocks provide income and long-term growth. Here’s how each can strengthen your retirement portfolio.","market":"nz","thumbnail":"https://thesmartinvestor.com.sg/wp-content/uploads/2025/11/CPF-vs-Dividend-Stocks-300x200.png","type":0,"news_type":0,"thumbnails":["https://thesmartinvestor.com.sg/wp-content/uploads/2025/11/CPF-vs-Dividend-Stocks-300x200.png"],"rights":{"source":"thesmartinvestor_highlight","url":"https://thesmartinvestor.com.sg/cpf-vs-dividend-stocks-which-builds-a-stronger-retirement-portfolio/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thesmartinvestor.com.sg/cpf-vs-dividend-stocks-which-builds-a-stronger-retirement-portfolio/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thesmartinvestor_highlight","symbols":["C2PU.SI","SGXZ58947870.SGD","SG9999002224.SGD","SG9999000418.SGD","CPF","LU0868494708.USD","IE00BVYPNP33.GBP","STI.SI","CFA.SI","LU0588545490.SGD","LU0345769631.USD","IE00BVYPNQ40.USD","S68.SI","MA","LU0315178854.USD","LU1551013425.SGD","LU0276348264.USD","LU0823417653.USD","SGXZ43160589.SGD","IE00BQXX3F31.USD","LU0823413660.USD","BK4533","LU2456880835.USD","LU0128522157.USD","LU2238330802.EUR","LU0823397103.USD","LU2250418816.HKD","LU1119993845.HKD","LU0557290698.USD","SG9999002406.SGD","IE00BFXG0V08.USD","SG9999001424.SGD","IE00BQXX3D17.EUR","LU0868494617.USD","LU0345775950.USD","LU0878004406.USD","LU0882747503.HKD","LU1989764748.USD","LU0205439572.USD","LU0390134368.USD","RA","LU0689472784.USD","LU0061475181.USD","LU2462157665.USD","BK6033","LU0942090050.USD","IE00BQXX3C00.GBP","LU0441851309.USD"],"gpt_icon":1},{"id":"2582734693","title":"Press Release: Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2582734693","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582734693?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948800,"startTime":"0","endTime":"0","summary":"Over 100 patients treated with AlloNK across autoimmune and oncology indications. Refractory rheumatoid arthritis  prioritized as lead indication following FDA Fast Track Designation for AlloNK, the first known therapy within the emerging deep B-cell depletion category to receive this designation in RA. Company to host webcast later this morning to discuss initial safety and translational data from clinical trials evaluating AlloNK in combination with anti-CD20 monoclonal antibodies across autoimmune diseases; presentation to also include outpatient feasibility and tolerability observations. Initial clinical response data in refractory RA expected in the first half of 2026, with FDA discussions planned to align on potential pivotal trial design in refractory RA. Cash runway into Q2 2027, with cash, cash equivalents, and investments of $123.0 million as of September 30, 2025. SAN DIEGO, Nov. 12, 2025  -- Artiva Biotherapeutics, Inc.  , a clinical-stage biotechnology company whose missio","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","R","BK4232","BK4139","RA","BK4022"],"gpt_icon":0},{"id":"2582010874","title":"Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2582010874","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582010874?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:35","pubTimestamp":1762781700,"startTime":"0","endTime":"0","summary":"The Company’s operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184603/0/en/Ernexa-Therapeutics-Reports-Strong-Quarterly-Performance-Highlighting-Operational-Execution-and-Progress-Toward-First-in-Human-Cell-Therapy-Trials.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PROC","PRGS","BK4007","LU2065732104.USD","BK4539","LENZ","RA","BK4097","ERNA"],"gpt_icon":0},{"id":"2582865090","title":"Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2582865090","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582865090?lang=en_us&edition=fundamental","pubTime":"2025-11-09 00:45","pubTimestamp":1762620300,"startTime":"0","endTime":"0","summary":"Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile Telitacicept demonstrated a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/08/3184078/0/en/Telitacicept-Achieved-Primary-Endpoint-of-Reducing-Proteinuria-in-Stage-A-of-a-Phase-3-Clinical-Study-for-IgA-Nephropathy-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","LU1223082519.USD","BK4077","SSI","SLE","CDE","LU1223082196.USD","BK4017","LU1223083913.SGD"],"gpt_icon":0},{"id":"2579584751","title":"Brookfield Real Assets Income Fund Inc. Announces Portfolio Manager Update Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2579584751","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579584751?lang=en_us&edition=fundamental","pubTime":"2025-10-30 06:19","pubTimestamp":1761776340,"startTime":"0","endTime":"0","summary":"NEW YORK, Oct.  29, 2025  (GLOBE NEWSWIRE) -- Brookfield Public Securities Group LLC (“PSG”) will host a webcast for Brookfield Real Assets Income Fund Inc. (NYSE: RA) (the “Fund”) on Wednesday, Novem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176982/0/en/Brookfield-Real-Assets-Income-Fund-Inc-Announces-Portfolio-Manager-Update-Webcast.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMBS","CMBS","RA","BK4141","BK4585"],"gpt_icon":0},{"id":"2579930188","title":"Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2579930188","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579930188?lang=en_us&edition=fundamental","pubTime":"2025-10-29 23:01","pubTimestamp":1761750060,"startTime":"0","endTime":"0","summary":"Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176649/0/en/Telitacicept-Demonstrates-Sustained-Efficacy-and-Favorable-Safety-Profile-in-48-Week-China-Phase-3-Open-Label-Extension-Generalized-Myasthenia-Gravis-Data.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","SLE","BK4077","BK4178","AAN"],"gpt_icon":0},{"id":"2579790195","title":"Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2579790195","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579790195?lang=en_us&edition=fundamental","pubTime":"2025-10-29 21:15","pubTimestamp":1761743700,"startTime":"0","endTime":"0","summary":"New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced thera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176538/0/en/Anaptys-Announces-New-Positive-Phase-2b-Trial-Results-for-Rosnilimab-in-Rheumatoid-Arthritis-at-ACR-Late-Breaking-Oral-Presentation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","BK4110","ACR"],"gpt_icon":0},{"id":"2578964388","title":"Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2578964388","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578964388?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:00","pubTimestamp":1761562800,"startTime":"0","endTime":"0","summary":"KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to appro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174428/0/en/Kymera-Therapeutics-Presents-New-Preclinical-Data-for-KT-579-a-First-in-Class-Oral-IRF5-Degrader-at-the-American-College-of-Rheumatology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4107","ACR","BK4110","BK4117","LU0541501648.USD","LU0541502299.USD","BK4139","IBD","BK4115","KT","AFG","RA"],"gpt_icon":0},{"id":"2576005922","title":"Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576005922","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576005922?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:00","pubTimestamp":1760702400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Oct.  17, 2025  (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical dat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168567/0/en/Vor-Bio-Announces-Late-Breaking-Oral-Presentation-of-China-Phase-3-IgA-Nephropathy-Clinical-Study-at-American-Society-of-Nephrology-s-Kidney-Week-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","LU1223083913.SGD","CDE","SLE","BK4107","BK4017","BK4117","BK4077","LU1223082196.USD","AFG","LU1223082519.USD"],"gpt_icon":0},{"id":"2575874502","title":"Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2575874502","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575874502?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:00","pubTimestamp":1760616000,"startTime":"0","endTime":"0","summary":"Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo Dual inhibition of BAFF an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/16/3167846/0/en/Vor-Bio-Announces-Publication-of-China-Phase-3-Study-of-Telitacicept-in-Systemic-Lupus-Erythematosus-in-The-New-England-Journal-of-Medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","RA","BK4077"],"gpt_icon":0},{"id":"2575290639","title":"Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575290639","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575290639?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:00","pubTimestamp":1760443200,"startTime":"0","endTime":"0","summary":"Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-po","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/14/3166097/0/en/Telitacicept-Demonstrates-Clinically-Meaningful-and-Statistically-Significant-Impact-on-ESSDAI-Compared-to-Placebo-in-Late-Breaking-China-Phase-3-Results-in-Primary-Sj%C3%B6gren-s-Disea.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4110","SLE","ACR","RA"],"gpt_icon":0},{"id":"2575863404","title":"Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575863404","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575863404?lang=en_us&edition=fundamental","pubTime":"2025-10-13 21:15","pubTimestamp":1760361300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  13, 2025  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165570/0/en/Anaptys-Announces-Late-Breaking-Oral-Presentation-of-Complete-Phase-2b-Data-for-Rosnilimab-in-Rheumatoid-Arthritis-at-Upcoming-ACR-Convergence-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR","BK4110","RA"],"gpt_icon":0},{"id":"2572309070","title":"RA Capital discloses increased PepGen stake at 29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2572309070","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572309070?lang=en_us&edition=fundamental","pubTime":"2025-10-01 09:25","pubTimestamp":1759281905,"startTime":"0","endTime":"0","summary":"In a regulatory filing, RA Capital disclosed it has increased its stake in PepGen (PEPG) by 9.4M shares or $30M. Shares of PepGen are up 3% afterho...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ra-capital-discloses-increased-pepgen-stake-at-29-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ra-capital-discloses-increased-pepgen-stake-at-29-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RA","BK4139","PEPG"],"gpt_icon":0},{"id":"2571835099","title":"Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2571835099","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571835099?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:05","pubTimestamp":1759176300,"startTime":"0","endTime":"0","summary":"Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manag","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3158108/0/en/Anaptys-Announces-Intent-to-Separate-Biopharma-Operations-from-Substantial-Royalty-Assets-by-Year-end-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPP","BK4144","RA","BK4590"],"gpt_icon":0},{"id":"2571350992","title":"ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®","url":"https://stock-news.laohu8.com/highlight/detail?id=2571350992","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571350992?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:05","pubTimestamp":1759176300,"startTime":"0","endTime":"0","summary":"Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept.  29, 2025  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3158104/0/en/ARS-Pharmaceuticals-Secures-Up-to-250-Million-Loan-Facility-with-RA-Capital-Management-and-OMERS-Life-Sciences-to-Accelerate-U-S-Commercialization-of-neffy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAQC","RA"],"gpt_icon":0},{"id":"2571387981","title":"Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2571387981","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571387981?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:00","pubTimestamp":1759143600,"startTime":"0","endTime":"0","summary":"BOSTON, Sept.  29, 2025  (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3157572/0/en/Vor-Bio-Announces-Late-Breaking-Poster-Presentation-of-Phase-3-Primary-Sj%C3%B6gren-s-Disease-Clinical-Study-at-ACR-Convergence-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","BK4077","SLE","CDE","LU1223083913.SGD","LU1223082519.USD","RA","BK4017","LU1223082196.USD","ACR"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40,"code":"91000000","status":"200"}]}}